Efficacy of pentoxifylline in Peyronie’s disease: Clinical case of a young man


Submitted: October 10, 2014
Accepted: October 10, 2014
Published: September 30, 2014
Abstract Views: 2988
PDF: 1574
SUPPLEMENTARY MATERIAL: 388
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Peyronie’s disease (PD) is a localized connective tissue disorder of the tunica albuginea of the penis and its surrounding tissue which results in a painful erection, penile curvature and erectile dysfunction. The great number and variety of purposed treatments for PD is in proportion to the difficulty of its management.In fact no medical treatment is currently available to cure patients with PD. Pentoxifylline (PTX) is a non specific phosphodiesterase inhibitor with anti-inflammatory properties that has been used to treat claudication. PTX has also been used to decrease inflammation and fibrosis in kidney transplants, open heart surgery, dermatological conditions and after radiation injury. With respect to penile diseases, clinical studies have suggested that PTX decreases calcification in new-onset PD. These traits make PTX an interesting potential option for PD therapy.

Dell’Atti, L., & Ughi, G. (2014). Efficacy of pentoxifylline in Peyronie’s disease: Clinical case of a young man. Archivio Italiano Di Urologia E Andrologia, 86(3), 237–238. https://doi.org/10.4081/aiua.2014.3.237

Downloads

Download data is not yet available.

Citations